IPG Investment Advisors LLC Makes New $1.55 Million Investment in Intuitive Surgical, Inc. $ISRG

IPG Investment Advisors LLC acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 2,736 shares of the medical equipment provider’s stock, valued at approximately $1,550,000.

Several other institutional investors have also recently made changes to their positions in ISRG. Northwestern Mutual Wealth Management Co. grew its stake in shares of Intuitive Surgical by 1,043.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,342,121 shares of the medical equipment provider’s stock worth $760,124,000 after acquiring an additional 1,224,734 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Intuitive Surgical by 106.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,533,771 shares of the medical equipment provider’s stock worth $868,667,000 after acquiring an additional 791,516 shares in the last quarter. Amundi grew its stake in shares of Intuitive Surgical by 29.7% in the 3rd quarter. Amundi now owns 3,227,472 shares of the medical equipment provider’s stock worth $1,451,362,000 after acquiring an additional 739,444 shares in the last quarter. Sands Capital Management LLC grew its stake in shares of Intuitive Surgical by 77.0% in the 3rd quarter. Sands Capital Management LLC now owns 1,341,109 shares of the medical equipment provider’s stock worth $599,784,000 after acquiring an additional 583,539 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of Intuitive Surgical by 41.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,941,310 shares of the medical equipment provider’s stock worth $868,212,000 after acquiring an additional 567,483 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

ISRG opened at $418.55 on Thursday. The firm has a market cap of $148.23 billion, a P/E ratio of 50.73, a PEG ratio of 3.49 and a beta of 1.51. The firm has a 50-day moving average of $455.79 and a 200 day moving average of $507.97. Intuitive Surgical, Inc. has a fifty-two week low of $414.30 and a fifty-two week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.08 by $0.42. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The firm’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.81 earnings per share. Equities research analysts predict that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ISRG shares. Zacks Research lowered shares of Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Wall Street Zen lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Sunday. Argus reduced their target price on shares of Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Piper Sandler reduced their target price on shares of Intuitive Surgical from $620.00 to $580.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. Finally, TD Cowen reduced their target price on shares of Intuitive Surgical from $660.00 to $585.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Nineteen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $576.71.

Insider Activity at Intuitive Surgical

In related news, EVP Gary Loeb sold 400 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $446.95, for a total transaction of $178,780.00. Following the completion of the transaction, the executive vice president owned 6,120 shares in the company, valued at approximately $2,735,334. This represents a 6.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia L. Wadors sold 220 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $499.71, for a total transaction of $109,936.20. The SEC filing for this sale provides additional information. Insiders have sold 5,701 shares of company stock valued at $2,783,807 in the last 90 days. 0.60% of the stock is currently owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.